Announcements Trials

Browse Landscape

Status

Recruiting 1 Completed 1

Sponsor Class

Study Type

Observational 1

Sponsor

Conditions

Recurrence 1 Neoplasms 1 Mouth Neoplasms 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Head and Neck Neoplasms 1

Interventions

Cyclophosphamide 21 venetoclax 18 pembrolizumab 16 Dexamethasone 16 fludarabine 14 Cytarabine 13 Gemcitabine 9 pomalidomide 8 Rituximab 8 Carboplatin 8 Azacitidine 8 glofitamab 7 fludarabine phosphate 7 Lenalidomide 7 Immunotherapy, Adoptive 7 selinexor 6 Paclitaxel 6 Injections 6 Granulocyte Colony-Stimulating Factor 6 Cisplatin 6 daratumumab 5 Temozolomide 5 Oxaliplatin 5 Bevacizumab 5 zanubrutinib 4 ruxolitinib 4 Surgical Procedures, Operative 4 Nivolumab 4 Drug Therapy 4 Decitabine 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Recurrence × High-Throughput Nucleotide Sequencing × Clear all

NCT05504772 2024-07-17

ZERO2

Australian & New Zealand Children's Haematology/Oncology Group

Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡